

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1-68. (canceled)

69. (currently amended): A method of delivering a substance into an intradermal compartment of a human subject's skin, said method comprising administering the substance through at least one small gauge hollow needle having an outlet with an exposed height between 0 and 1 mm, said outlet being inserted into the skin to a depth of between 0.3 mm and 2 mm, such that delivery of the substance occurs at a depth between 0.3 mm and 2 mm, wherein a dosage of the substance for achieving a systemic bioavailability of the substance is reduced by at least 10% compared to the dose required to achieve the systemic bioavailability when the substance is delivered to a subcutaneous compartment of the human subject's skin.

70. (previously presented): The method of claim 69, wherein the systemic bioavailability results in a therapeutic or diagnostic effect.

71. (previously presented): The method of claim 69 wherein the administering comprises inserting the needle so that the substance is deposited at a depth of at least about 0.3 mm below the surface of the human subject's skin to no more than about 2 mm below the surface of the human subject's skin.

72. (previously presented): The method of claim 69 wherein the administering comprises inserting the needle into the skin so that the substance is deposited at a depth of at least about 0.3 mm and no more than about 2 mm.

73. (previously presented): The method of claim 69 wherein the substance is administered over a time period of not more than ten minutes.

74. (currently amended): The method of claim 69 wherein the substance is administered at a rate between 1 nL/min ~~nL/min~~ and 200 mL/ min.
75. (previously presented): The method of claim 69 wherein the needle(s) are inserted substantially perpendicularly to the skin.
76. (canceled)
77. (previously presented): The method of claim 69 wherein the dosage is reduced by at least 20%.
78. (previously presented): The method of claim 69 wherein the dosage is reduced by at least 30%.
79. (previously presented): The method of claim 69 wherein the substance is a peptide, protein or nucleic acid.
80. (previously presented): The method of claim 69 wherein the substance is a diagnostic or therapeutic substance.
81. (previously presented): The method of claim 69 wherein the substance is hydrophobic.
82. (previously presented): The method of claim 69 wherein the substance is hydrophilic.
83. (previously presented): The method of claim 69 wherein the substance is a hormone.
84. (previously presented): The method of claim 69 wherein the substance is selected from the group consisting of insulin, granulocyte stimulating factor and PTH.
85. (currently amended): A method of delivering a substance into an intradermal compartment of a human subject's skin, said method comprising injecting or infusing the substance intradermally through one or more microneedles having a length sufficient to

penetrate the intradermal compartment and an outlet at a depth within the intradermal compartment wherein a dosage of the substance for achieving a systemic bioavailability of the substance is reduced by at least 10% compared to the dose required to achieve the systemic bioavailability when the substance is delivered to a subcutaneous compartment of the human subject's skin.

86. (previously presented): The method of claim 85 wherein the length of the microneedle(s) is from about 0.5 mm to about 1.7 mm.

87. (previously presented): The method of claim 85 wherein the microneedle is a 30 to 34 gauge needle.

88. (currently amended): The method of claim 85 wherein the microneedle has an outlet with an exposed height between ~~depth of from 0 and to~~ 1 mm.

89. (previously presented): The method of claim 85 wherein the microneedle is configured in a delivery device which positions the microneedle perpendicular to skin surface.

90. (previously presented): The method of claim 85 wherein the microneedle is contained in an array of microneedles.

91. (previously presented): The method of claim 90 wherein the array comprises 3 microneedles.

92. (previously presented): The method of claim 90 wherein the array comprises 6 microneedles.

93. (previously presented): The method of claim 85 wherein the substance is administered over a time period of not more than ten minutes.

94. (currently amended): The method of claim 85 wherein the substance is administered at a rate between 1 nL/min ~~nL/min~~ and 200 mL/min.

95. (previously presented): The method of claim 85 wherein the microneedle(s) are inserted substantially perpendicularly to the skin.
96. (canceled)
97. (previously presented): The method of claim 85 wherein the dosage is reduced by at least 20%.
98. (previously presented): The method of claim 85 wherein the dosage is reduced by at least 30%.
99. (previously presented): The method of claim 85 wherein the substance is a peptide, protein, or nucleic acid.
100. (previously presented): The method of claim 85 wherein the substance is a hormone.
101. (previously presented): The method of claim 85 wherein the substance is hydrophobic.
102. (previously presented): The method of claim 85 wherein the substance is hydrophilic.
103. (previously presented): The method of claim 85 wherein the substance is selected from the group consisting of insulin, granulocyte stimulating factor and PTH.
104. (previously presented): The method of claim 69 or 85 wherein the substance is used for the treatment of a symptom of a pathological condition.
105. (new): The method of claim 85, wherein delivery of the substance occurs at a depth between 0.3 to 2.0 mm

106. (new): The method of claim 69, wherein the systemic bioavailability is measured by a determination of  $t_{lag}$ ,  $T_{max}$ ,  $C_{max}$  or AUC.

107. (new): The method of claim 85, wherein the systemic bioavailability is measured by a determination of  $t_{lag}$ ,  $T_{max}$ ,  $C_{max}$  or AUC.